ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Harmony Biosciences Holdings, Inc. ?
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 27.07%
- Healthy long term growth as Net Sales has grown by an annual rate of 40.30% and Operating profit at 65.13%
- The company is Net-Debt Free
2
With a growth in Net Profit of 89.64%, the company declared Very Positive results in Jun 26
- OPERATING CASH FLOW(Y) Highest at USD 355.07 MM
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- CASH AND EQV(HY) Highest at USD 1,308.71 MM
3
With ROE of 18.24%, it has a attractive valuation with a 1.76 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 26.22%, its profits have risen by 9.1% ; the PEG ratio of the company is 1.2
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 26.22% in the last 1 year, much higher than market (S&P 500) returns of 15.76%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Harmony Biosciences Holdings, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Harmony Biosciences Holdings, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Harmony Biosciences Holdings, Inc.
53.81%
0.68
52.28%
S&P 500
16.06%
1.20
13.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
40.30%
EBIT Growth (5y)
65.13%
EBIT to Interest (avg)
6.67
Debt to EBITDA (avg)
0.20
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
0.82
Tax Ratio
22.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
45.85%
ROE (avg)
27.07%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.76
EV to EBIT
4.75
EV to EBITDA
4.24
EV to Capital Employed
3.04
EV to Sales
1.14
PEG Ratio
1.21
Dividend Yield
NA
ROCE (Latest)
64.06%
ROE (Latest)
18.24%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 355.07 MM
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
CASH AND EQV(HY)
Highest at USD 1,308.71 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 41.69 times
NET SALES(Q)
Highest at USD 261.28 MM
OPERATING PROFIT(Q)
Highest at USD 95.28 MM
OPERATING PROFIT MARGIN(Q)
Highest at 36.47 %
PRE-TAX PROFIT(Q)
Highest at USD 93.27 MM
NET PROFIT(Q)
Highest at USD 75.43 MM
EPS(Q)
Highest at USD 1.28
-3What is not working for the Company
ROCE(HY)
Lowest at 20.46%
RAW MATERIAL COST(Y)
Grown by 5.81% (YoY
Here's what is working for Harmony Biosciences Holdings, Inc.
Operating Cash Flow
Highest at USD 355.07 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 261.28 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Sales
At USD 261.28 MM has Grown at 30.32%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 95.28 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 36.47 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 93.27 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD 93.27 MM has Grown at 87.89%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 75.43 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Profit
At USD 75.43 MM has Grown at 89.64%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 1.28
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 1,308.71 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 41.69 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Here's what is not working for Harmony Biosciences Holdings, Inc.
Raw Material Cost
Grown by 5.81% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
